Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Corcept Therapeutics (NASDAQ:CORT) and raises the price target from $35 to $38.
July 30, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst David Amsellem maintains an Overweight rating on Corcept Therapeutics and raises the price target from $35 to $38.
The raised price target and maintained Overweight rating from a reputable analyst at Piper Sandler is likely to positively impact investor sentiment and drive short-term price appreciation for Corcept Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100